The crush of year-end sales and earnings reports brought numerous disclosures of new applications to FDA for approval, including a new molecular entity from Celgene Corp. and a novel biologic from AstraZeneca PLC.
In the meantime, FDA issued approvals for new claims, new formulations,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?